Cras

The impact of regulatory changes on rating behaviour

Retrieved on: 
Tuesday, April 2, 2024
Długosz, Disagreement, Pi bond, Direct lending, Key, Research Papers in Economics, Finance Secretary (India), University of Oxford, STS, Journal of Economic Perspectives, International, American Economic Review, Life, Columbia Business School, British Academy of Management, Risk assessment, ABS, Rating, EBA, Development, Reputational damage, OBS, CRA, Bond credit rating, Cras, Journal of Monetary Economics, CDO, Becker, Paper, 2007–2008 financial crisis, Raja, University, Environment, Journal of Financial Economics, Perception, H3, Website, Securitization, Working paper, Market, Collection, Total, European Banking Authority, Quarterly Journal of Economics, BBB, Whetten, Column, ESMA, European Journal, Issuer, Asset quality, Information revolution, Federal Reserve Bank, OLS, Statistics, PDF, Private, ECB, Surety, Weighted-average life, CCC, European Commission, Social science, Journal of Financial Stability, JEL, Real, Bias, Journal, Research, Classification, Certification, Commission, Credit, The Journal of Finance, Literature, Karel Škréta, European Central Bank, AA, Finance Research Letters, Origination (telephony), Monetary economics, Section 5, Xia, Kraft Foods, Government, AAA, Mukherjee, Finance, Deku, DOI, White, Risk, IOSCO, MBS, OECD, Wang, Section 4, University Challenge 2013–14, Section 3, Ashcraft, Financial management, Accounting, Financial economics, Fannie Mae, Conference, Pressure, Central bank, Griffin, University of Michigan, Systematic review, EPRS, Freddie Mac, Loan, BCBS, Palgrave Macmillan, R2, Microeconomics, Quarterly Journal, Financial statement analysis, The Japanese Economic Review, Christian Social Union (UK), Green, University of Huddersfield, PSM, Management, Security (finance), Security, Civil service commission, Private placement, American Economic Journal, GFC, Reproduction, IMF, Small business, Trustee, Data

Abstract

Key Points: 
    • Abstract
      We examine rating behaviour after the introduction of new regulations regarding Credit Rating
      Agencies (CRAs) in the European securitisation market.
    • There is empirical evidence of rating catering in the securitisation market in the pre-GFC period (He et al.,
      2012; Efing and Hau, 2015).
    • Competition among
      CRAs could diminish ratings quality (Golan, Parlour, and Rajan, 2011) and promotes rating shopping by
      issuers resulting in rating inflation (Bolton et al., 2012).
    • This paper investigates the impact of the post-GFC regulatory changes in the European
      securitisation market.
    • In 2011, in addition to the creation of
      European Securities and Markets Authority (ESMA), a regulatory and supervisory body for CRAs was
      introduced.
    • We examine how rating behaviours have changed in the European securitisation market after the
      introduction of these new regulations.
    • We utilise the existence of multiple ratings and rating agreements between
      CRAs to identify the existence of rating shopping and rating catering, respectively (Griffin et al., 2013; He
      et al., 2012; 2016).
    • We find that the regulatory changes have been effective in tackling conflicts of interest between issuers
      and CRAs in the structured finance market.
    • Rating catering, which is a direct consequence of issuer and
      CRA collusion, seems to have disappeared after the introduction of these regulations.
    • There is empirical evidence of rating catering in the securitisation market in
      the pre-GFC period (He et al., 2012; Efing and Hau, 2015).
    • Competition among CRAs could diminish ratings quality (Golan, Parlour,
      and Rajan, 2011) and promotes rating shopping by issuers resulting in rating inflation (Bolton et
      al., 2012).
    • This paper investigates the impact of the post-GFC regulatory changes in the European
      securitisation market.
    • In 2011, in addition
      to the creation of European Securities and Markets Authority (ESMA), a regulatory and
      supervisory body for CRAs was introduced.
    • We find that the regulatory changes have been effective in tackling conflicts of interest
      between issuers and CRAs in the structured finance market.
    • Rating catering, which is a direct
      consequence of issuer and CRA collusion, seems to have disappeared after the introduction of
      these regulations.
    • Investors who previously demanded higher spreads for rating agreements for a
      multiple rated tranche, did not consider the effect of rating harmony as a risk in the post-GFC
      period.
    • Regarding rating shopping, we find that the effectiveness of the changes has been limited,
      potentially for two reasons.
    • Additionally, we also find that rating over-reliance might still be an issue, especially
      Rating catering is a broad term and it can involve rating shopping.
    • They re-examine the rating shopping and rating
      catering phenomena in the US market by looking at the post-crisis period between 2009 and 2013.
    • Using 622 CDO tranches, they also observe the existence of rating shopping and the diminishing
      of the rating catering.
    • Firstly, our main focus is the EU?s CRA Regulation and its effectiveness in reducing
      rating inflation and rating over-reliance.
    • To the best of our knowledge, this paper is the first to
      examine the effectiveness of the EU?s CRA regulatory changes on the investors? perception of
      rating inflation in the European ABS market.
    • Hence, the coverage and quality of our dataset constitutes significant addition
      to the literature and allows us to test the rating shopping and rating catering more authoritatively.
    • The following section reviews the literature
      on securitisation concerning CRAs and conflicts of interest, and outlines the regulatory changes
      introduced in the post-GFC period.
    • Firstly, ratings became ever more important as the Securities and
      Exchange Commission (SEC) 5 began heavily relying on CRA assessments for regulatory purposes
      (i.e.
    • the investment mandates that highlight rating agencies as the main benchmark for investment
      eligibility) (SEC, 2008; Kisgen and Strahan, 2010; Bolton et al., 2012).
    • issuers) as one of the main explanations for the rating inflation (He et al., 2011; 2012; Bolton
      et al., 2012; Efing and Hau, 2015).
    • Bolton et al., (2012) demonstrate that competition
      promotes rating shopping by issuers, leading to rating inflation.
    • The last phase, CRA III, was implemented in mid-2013 and involves an additional
      set of measures on reducing transparency and rating over-reliance.
    • As mentioned above, rating inflation can be caused by rating shopping
      In order to be eligible to use the STS classification, main parties (i.e.
    • The higher the difference in the number of ratings for a
      given ABS tranche, the greater the risk of rating shopping.
    • Alternatively, the impact of the new
      regulations could be limited when it comes to reducing rating shopping.
    • This is because, firstly,
      the conflict of interest between securitisation parties is not necessarily the sole cause for the
      occurrence of rating shopping.
    • L is a set of variables (Multiple ratings, CRA reported, Rating agreement) that
      we utilise interchangeably to capture the rating shopping and rating catering behaviour.
    • Hence, issuers are incentivised to report the highest possible rating and
      ensure each additional rating matches the desired level.
    • All in all, our results suggest that
      the new stricter regulatory measures have been effective in tackling conflicts of interest and
      reducing rating inflation caused by rating catering.
    • Self-selection might be a concern in analysing the impact of the
      new measures and investors? response with regard to the rating inflation.
    • This
      result is in line with the earlier findings suggesting that regulatory changes have reduced investors?
      suspicion of rating inflation and increased trust of CRAs.
    • Conclusion
      Several regulatory changes were introduced in Europe following the GFC aimed at tackling
      conflicts of interest between issuers and CRAs in the ABS market.
    • Utilising a sample of 12,469
      ABS issued between 1998 and 2018 in the European market, this paper examined whether these
      changes have had any impact on rating inflations caused by rating shopping and rating catering
      phenomena.
    • We find that the
      effectiveness of the changes has been more limited on rating shopping potentially for two reasons.
    • Tranche Credit Rating is the rating reported for a tranche at launch.

Trialbee Releases New Features for the Insights Module in the Honey Platform™ to Enhance ROI Analysis and Patient Recruitment Projections in Global Clinical Trials

Retrieved on: 
Monday, February 12, 2024

CHAPEL HILL, N.C., and MALMÖ, Sweden, Feb. 12, 2024 /PRNewswire-PRWeb/ -- Trialbee, the global leader in technology-based patient recruitment for clinical trials, has introduced key features for the Insights Module in its Honey Platform™ to provide even greater visibility into recruitment ROI and projections. These enhancements include…

Key Points: 
  • These enhancements include…
    A full-funnel ROI calculator across all sources, regions, channels, and individual tactics
    The Honey Platform already transforms patient recruitment for global trials with unprecedented transparency and actionable data analytics.
  • These new features in its Insights Module allow sponsors to make even better data-driven decisions that improve recruitment outcomes.
  • "What makes the Honey Platform unique is that it is the only Patient Recruitment Platform built by, used by, and surrounded by true patient recruitment experts," said Oskar Daniel , Trialbee Honey Product Manager.
  • To experience how Trialbee is revolutionizing the patient recruitment ecosystem through technology, people, and passion, visit https://www.trialbee.com .

Lavoro Announces a New R$420 Million 4-Year Secured Credit Facility

Retrieved on: 
Wednesday, December 27, 2023

SÃO PAULO, Brazil, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Lavoro Limited (Nasdaq: LVRO), the first U.S.-listed pure-play agricultural inputs retailer in Latin America, today announced the establishment of a new R$420 million (equivalent to approximately $86 million USD based on current exchange rates) secured credit facility with a 4-year term (the “Credit Facility”).

Key Points: 
  • SÃO PAULO, Brazil, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Lavoro Limited (Nasdaq: LVRO), the first U.S.-listed pure-play agricultural inputs retailer in Latin America, today announced the establishment of a new R$420 million (equivalent to approximately $86 million USD based on current exchange rates) secured credit facility with a 4-year term (the “Credit Facility”).
  • Lavoro Agro Holdings S.A., a Lavoro Limited subsidiary in Brazil, is the issuer of the CRAs as part of the Credit Facility.
  • All told, this move is a valuable step in supporting our long-term growth objectives.”
    The Credit Facility is split in two separate series (“Series”) maturing in December 2027.
  • The issuance of the Credit Facility was carried out in collaboration with EcoAgro Group, a firm specialized in the structuring of CRAs.

TransPerfect Life Sciences Releases Trial Interactive 10.5

Retrieved on: 
Tuesday, November 28, 2023

NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- TransPerfect Life Sciences , a leading provider of services and technologies to support global clinical trials and product development for the biopharmaceutical industry, announced the release of version 10.5 of its award-winning Trial Interactive eClinical platform.

Key Points: 
  • NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- TransPerfect Life Sciences , a leading provider of services and technologies to support global clinical trials and product development for the biopharmaceutical industry, announced the release of version 10.5 of its award-winning Trial Interactive eClinical platform.
  • Trial Interactive’s user-friendly document and trial management automation helps pharmaceutical, biotechnology, and CRO companies effectively streamline product development lifecycles.
  • A fully connected solution, Trial Interactive offers fast-to-implement and cost-effective solutions in a secure 21 CFR Part 11-compliant environment.
  • “This update of Trial Interactive gives sponsors even more real-time oversight, process automation, and ease of use, as well as a feature-rich mobile experience,” said Michael Smyth, Division President of TransPerfect Life Sciences Solutions.

How the Illinois Transportation Benefits Program Act Affects Employers and Employees

Retrieved on: 
Wednesday, November 22, 2023

In July of 2023, the Illinois General Assembly passed the Transportation Benefits Program Act , mandating that employers who meet certain criteria must offer tax-advantaged benefits to employees commuting via public transit.

Key Points: 
  • In July of 2023, the Illinois General Assembly passed the Transportation Benefits Program Act , mandating that employers who meet certain criteria must offer tax-advantaged benefits to employees commuting via public transit.
  • Employers with at least 50 covered employees need to act quickly.
  • First American Bank’s Health Account Services team is dedicated to helping employers craft benefits offerings that support employee retention and seamless management.
  • The Transportation Benefits Program Act goes into effect January 1, 2024.

TransPerfect Life Sciences Releases Trial Interactive 10.5

Retrieved on: 
Tuesday, November 28, 2023

NEW YORK, Nov. 28, 2023 /PRNewswire/ -- TransPerfect Life Sciences, a leading provider of services and technologies to support global clinical trials and product development for the biopharmaceutical industry, announced the release of version 10.5 of its award-winning Trial Interactive eClinical platform. This new version is a significant update and brings new benefits to sponsors, enabling them to further automate oversight for proactive and predictive trial management.

Key Points: 
  • NEW YORK, Nov. 28, 2023 /PRNewswire/ -- TransPerfect Life Sciences , a leading provider of services and technologies to support global clinical trials and product development for the biopharmaceutical industry, announced the release of version 10.5 of its award-winning Trial Interactive eClinical platform.
  • Trial Interactive's user-friendly document and trial management automation helps pharmaceutical, biotechnology, and CRO companies effectively streamline product development lifecycles.
  • A fully connected solution, Trial Interactive offers fast-to-implement and cost-effective solutions in a secure 21 CFR Part 11-compliant environment.
  • "This update of Trial Interactive gives sponsors even more real-time oversight, process automation, and ease of use, as well as a feature-rich mobile experience," said Michael Smyth, Division President of TransPerfect Life Sciences Solutions.

Fortrea Completes Expansion of Clinical Pharmacology Solutions Following Targeted Investments at its Four Clinical Research Units in U.S. and U.K.

Retrieved on: 
Thursday, November 2, 2023

“Our integrated platform of services includes best-in-class infrastructure and experienced professionals who are fully dedicated to clinical pharmacology, including physicians, nurses, clinical scientists, CRAs and pharmacokineticists.

Key Points: 
  • “Our integrated platform of services includes best-in-class infrastructure and experienced professionals who are fully dedicated to clinical pharmacology, including physicians, nurses, clinical scientists, CRAs and pharmacokineticists.
  • Improvements in recreational, living and “work-from-home” spaces at Fortrea CRUs have been constructed to enhance the experience of volunteers participating in research at the sites.
  • The expansion of Fortrea’s early clinical development pharmacy services facilities includes new state-of-the-art cGMP pharmacies in the Leeds and Daytona CRUs.
  • “I believe Fortrea’s early clinical development solutions set a new standard for what the research industry should expect from its partners,” said Dr. Cohen.

InformData Appoints John Hanks as Director of Public Record Partnerships

Retrieved on: 
Thursday, October 19, 2023

ATLANTA, Oct. 19, 2023 /PRNewswire-PRWeb/ -- InformData, a leading provider of people data and information solutions, is pleased to announce the appointment of John Hanks as the company's Director of Public Record Partnerships. Mr. Hanks brings a wealth of experience and expertise to this critical role, further strengthening InformData's commitment to delivering high-quality direct-source data and information services to its clients.

Key Points: 
  • ATLANTA, Oct. 19, 2023 /PRNewswire-PRWeb/ -- InformData, a leading provider of people data and information solutions , is pleased to announce the appointment of John Hanks as the company's Director of Public Record Partnerships.
  • In his new role as Director of Public Record Partnerships, John will be responsible for developing and nurturing relationships with the company's proprietary network of public record researchers and clerks of courts throughout the country.
  • With Mr. Hanks leading the public record partnerships division, clients can expect even greater access to the most reliable and current public records available.
  • The addition of John Hanks as the Director of Public Record Partnerships is a significant milestone for InformData, as the company strives to strengthen its position as a premier provider of data and information solutions.

Cebis Unveils Full Preclinical and Clinical Trial Services, Including Bio-Analytical Lab and Global Logistics

Retrieved on: 
Friday, October 6, 2023

Cebis Unveils Full Preclinical and Clinical Trial Services, Including Bio-Analytical Lab and Global Logistics

Key Points: 
  • Cebis Unveils Full Preclinical and Clinical Trial Services, Including Bio-Analytical Lab and Global Logistics
    To view an enhanced version of this graphic, please visit:
    "CEBIS is pleased to announce its expansion into the North American and Indian markets after more than 15 years of operation in the European Union," says Dr. Mihai Manolache, PhD - Chairman of the Board of Directors.
  • Representatives of the clinical trial industry with over two decades of experience in the field have decided to merge with CEBIS.
  • CEBIS International (Europe), Clinical Trial Network - CTN (United States of America), Globyz Clinical Solutions (Canada), Vayam Research Solutions (India), and Achiral Systems Private Limited (India) have signed definitive agreements.
  • With offices and operations in Boston, Philadelphia, and Chicago, as well as a global hub for clinical trial supplies in North America, R&D, Logistics, Clinical, and Pre-Clinical facilities (GLP accredited), and Technology & Innovation centers in Ahmedabad, Hyderabad, Chennai, Mumbai, and Bangalore, CEBIS can now support clinical research operations on three continents.

Zilch Announces the Official Launch of Zilch up, Which Provides Access to More Affordable Credit and Is Building Stronger Financial Futures

Retrieved on: 
Thursday, October 12, 2023

This will create access for millions to build their financial profiles safely and responsibly and without paying any interest.

Key Points: 
  • This will create access for millions to build their financial profiles safely and responsibly and without paying any interest.
  • View the full release here: https://www.businesswire.com/news/home/20231012901593/en/
    The introduction of Zilch Up provides all the benefits of Zilch’s zero-interest, ad-subsidised borrowing with the ability to improve your credit score, which wasn't possible before Zilch.
  • With 5 million people in the UK deemed credit invisible, Zilch’s new product enables customers with tools to improve their credit scores and increase their credit limit.
  • A user’s credit score improvement can only occur where a user’s credit reporting via Zilch is more up to date than with other lenders.